Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Pfizer Inc
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A study to evaluate the safety and efficacy of PF-06650833 in subjects with moderate to severely active rheumatoid arthritis who have an incomplete response to methotrexate treatment Estudio para evaluar la eficacia y seguridad de PF-06650833 en sujetos con artritis reumatoide de moderada a severa que han presentado una respuesta inadecuada a metotrexato (MTX)
To evaluate the efficacy of PF-06650833 at 12 weeks, in subjects with moderate - severe active RA who have had an inadequate response to methotrexate. Evaluar la eficacia de PF-06650833 a las 1...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
A 52-WEEK MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL, TWO - ARM STUDY COMPARING EXUBERA® (INHALED HUMAN INSULIN) VS. HUMALOG® (INSULIN LISPRO), BOTH IN COMBINATION WITH INSULIN GLARGINE IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS - PROTOCOL A2171035
The primary objective of the study is to demonstrate non-inferiority of an insulin regimen using insulin glargine as the basal insulin with Exubera as the mealtime insulin, compared to a regimen using...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc. 235 East 42nd Street, New York, 10017
Update Il y a 4 ans
Study to test whether PF-05212377 is safe and improves symptoms in patients with Alzheimer's disease with existing neuropsychiatric symptoms. Estudio para probar si PF-05212377 es seguro y si mejora los síntomas en pacientes con enfermedad de Alzheimer que presentan síntomas neuropsiquiátricos
To evaluate the efficacy of PF-05212377 (SAM-760) 30 mg QD as compared to placebo on the primary measure of cognition and memory, the Alzheimer?s Disease Assessment Scale ? cognitive subscale (13 item...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc
Update Il y a 4 ans
Study Evaluating the Pharmacokinetics, Efficacy and Safety of Sildenafil in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN) or Hypoxic Respiratory Failure and at Risk for PPHN
1. To evaluate the pharmacokinetics of intravenous (IV) sildenafil in near-term and term newborns with PPHN or with hypoxic respiratory failure and at risk for PPHN to determine doses for Part 2 of t...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE DOSES OF PF-04360365 IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
Primary Objectives: 1. To examine the safety and tolerability of PF-04360365 in subjects with mild-to moderate AD dosed for 18 months and followed for a total of 24 months; 2. To characterize the ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
A 52-WEEK OPEN-LABEL SAFETY STUDY OF PD 0332334 IN SUBJECTS WITH GENERALIZED ANXIETY DISORDER
Primary Objectives: • To assess the long-term safety and tolerability of 350 to 600 mg/day of PD-0332334 dosed BID in subjects with GAD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United states
Update Il y a 4 ans
AN 8 WEEK, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 3 TRIAL OF PREGABALIN (150 600 MG/DAY) IN THE ADJUNCTIVE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) WHO HAVE NOT OPTIMALLY RESPONDED TO EXISTING THERAPIES
The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo as an adjunctive treatment in patients with GAD who partially responded to a standard GAD treatment...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
Update Il y a 4 ans
Persistence of antibodies after meningococcal vaccine PF-06866681 in healthy children
Immunogenicity Persistence At 2, 3, 4, 5, 6 years after booster vaccination of children with MenACWY-TT or Meningitec •To evaluate the persistence of meningococcal antibodies in terms of the perce...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Pfizer Inc.235 East 42nd Street, New York, NY 10017
Update Il y a 4 ans
PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES
The primary objective of this study is to evaluate the analgesic efficacy of single dose tanezumab 10 mg in combination with opioids (tanezumab 10 mg + opioids compared with opioids alone (placebo + o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
Update Il y a 4 ans
To evaluate the safety and immunogenicity of a booster dose of meningococcal vaccine administered 10 years after primary vaccination of 1-10 year old subjects with MenACWY-TT (PF-06866681), Meningitec or Mencevax ACWY
•To evaluate the long-term persistence of the serum bactericidal (antibody) titres induced by MenACWY-TT vaccine as compared to Meningitec when administered to individuals 1-<2 years of age in terms o...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
13
14
15
16
17
18
19
20
21
22
Next